Login / Signup

Thrombo-inflammation response to Tocilizumab in COVID-19.

Mansour GergiAndrea N EdgintonBenjamin LittenbergRalph C Budd
Published in: Research and practice in thrombosis and haemostasis (2020)
These findings suggest both pathophysiological mechanisms as well as clinical benefit that might be seen with IL-6 inhibition in severe COVID-19.
Keyphrases
  • coronavirus disease
  • sars cov
  • rheumatoid arthritis
  • oxidative stress
  • respiratory syndrome coronavirus
  • early onset
  • rheumatoid arthritis patients